Page last updated: 2024-08-24

glucose, (beta-d)-isomer and Weight Reduction

glucose, (beta-d)-isomer has been researched along with Weight Reduction in 118 studies

Research

Studies (118)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (0.85)18.2507
2000's5 (4.24)29.6817
2010's93 (78.81)24.3611
2020's19 (16.10)2.80

Authors

AuthorsStudies
Crisafulli, C; Cuzzocrea, S; Di Bella, P; Di Paola, R; Esposito, E; Genovese, T; Mazzon, E; Meli, R; Menegazzi, M; Muià, C; Suzuki, H1
Dinarello, CA; Fantuzzi, G1
Behuliak, M; Hojná, S; Hüttl, M; Kadlecová, M; Kujal, P; Malínská, H; Marková, I; Miklánková, D; Neckář, J; Papoušek, F; Rauchová, H; Vaněčková, I; Vaňourková, Z; Zicha, J1
Han, Y; He, SM; Wang, DD; Wang, TY; Wang, YM1
Barkhof, F; IJzerman, RG; Kramer, MHH; Nieuwdorp, M; Schrantee, A; van Bloemendaal, L; van Ruiten, CC; Veltman, DJ1
Bodicoat, DH; Chatterjee, S; Davies, MJ; Edwardson, CL; Gray, LJ; Khunti, K; King, JA; Poulin, B; Redman, EL; Sargeant, JA; Stensel, DJ; Waheed, G; Waller, HL; Webb, DR; Wilding, JPH; Willis, SA; Yates, T1
IJzerman, RG; Kramer, MHH; Nieuwdorp, M; Ten Kulve, JS; van Ruiten, CC; Veltman, DJ; Wijdeveld, M1
IJzerman, RG; Nieuwdorp, M; van Ruiten, CC; Veltman, DJ1
Ananicheva, N; Andreev, D; Bogdanova, A; Charaya, K; Dyachuk, I; Kuzub, A; Mesitskaya, D; Poltavskaya, M; Shchekochikhin, D; Tarasenko, S1
Huh, Y; Kim, YS1
Ali, SN; Dang-Tan, T; Ericsson, Å; Hansen, BB; Hunt, B; Kallenbach, K; Malkin, SJP; Valentine, WJ1
Fuchigami, A; Higa, M; Hirose, T; Hiyoshi, T; Ichijo, T; Inoue, I; Iso, K; Kitazawa, T; Kumashiro, N; Okada, Y; Shigiyama, F; Yoshii, H1
Fujii, S; Gunji, R; Kakiuchi, S; Kaku, K; Kameda, H; Koshida, R; Kurihara, Y; Senda, M; Tamura, M; Utsunomiya, K1
Espinosa, E; Ferreira-Hermosillo, A; Garrido-Mendoza, AP; Mendoza-Zubieta, V; Mercado, M; Molina-Ayala, MA; Molina-Guerrero, D; Ramírez-Rentería, C1
Miyauchi, T1
Dias, DA; Gill, H; Hung, A; Lenon, GB; Li, M; Luo, S; Nguyen, LT1
Badakhshi, Y; Brubaker, PL; Jin, T; Ling, W; Ning, H; Shao, W; Song, Z; Tian, L; Yang, BB1
Ayers, CR; de Albuquerque Rocha, N; Hughes, C; Jin, ES; Malloy, CR; Neeland, IJ1
Aoki, S; Atsumi, T; Cho, KY; Kameda, H; Kurihara, Y; Miya, A; Miyoshi, H; Nakamura, A; Nomoto, H; Omori, K; Takase, T; Taneda, S; Yamamoto, K1
Aaron, M; Collins, SP; Cox, ZL; Davidson, BT; Fowler, M; Hernandez, GA; Iii, ATM; Jenkins, CA; Jr, FEH; Kampe, C; Lindenfeld, J; Lindsell, CJ; Miller, KF; Stubblefield, WB1
Fujihara, K; Kaku, K; Matsubayashi, Y; Oe, M; Sato, T; Sone, H; Suganami, H; Tanaka, S; Yaguchi, Y; Yamada, T; Yoshida, A1
Bellanger, D; Chappell, N; Elkind-Hirsch, KE; Seidemann, E; Storment, J1
Eriksson, JW; Johnsson, E; Katsogiannos, P; Lundkvist, P; Pereira, MJ; Sjöström, CD1
Amino, N; Hayashizaki, Y; Hirosumi, J; Kurosaki, E; Minoura, H; Takakura, S; Takasu, T1
Bailey, C; Blak, B; Emmas, C; Kok, M; Rigney, U; Wilding, J1
Black, RL; Irons, BK; Minze, MG; Terrell, BT; Will, KJ1
Broedl, UC; Cherney, DZI; Cooper, ME; Johansen, OE; Lund, SS; Pfarr, E; Tikkanen, I; Woerle, HJ1
Aita, Y; Iwasaki, H; Izumida, Y; Kadowaki, T; Kawakami, Y; Kobayashi, K; Kubota, M; Li, E; Masuda, Y; Matsuzaka, T; Murayama, Y; Nakagawa, Y; Nishi-Tatsumi, M; Piao, X; Sawada, Y; Sekiya, M; Shikama, A; Shimano, H; Sugano, Y; Suzuki, H; Takeuchi, Y; Wada, N; Yagyu, H; Yahagi, N; Yatoh, S1
Matsuba, I; Matsuba, R; Nagai, Y; Shimokawa, M; Tanaka, Y1
George, J; Hanafusa, T; Lee, G; Marquard, J; Sarashina, A; Shiki, K; Shimada, A; Soleymanlou, N; Taneda, Y; Yasui, A1
Forest, CP; Tat, V1
Inzucchi, SE; Lupsa, BC1
Cherney, DZI; Thomas, MC1
Dandona, P; Hansen, L; Langkilde, AM; Mathieu, C; Phillip, M; Thorén, F; Tschöpe, D; Xu, J1
Dong, P; Liu, H; Zhao, D1
Ares, J; Delgado, E; Maciá, C; Menéndez, E; Pujante, P; Rodriguez Escobedo, R1
Hara, K; Hirota, Y; Kishi, M; Komada, H; Kuroki, Y; Matsuda, T; Miura, H; Ogawa, W; Ohara, T; Okada, Y; Otowa-Suematsu, N; Sakaguchi, K; So, A; Takeda, A; Tamori, Y; Yamada, T; Yokota, K1
Maegawa, H; Nakamura, I; Tabuchi, H; Tobe, K; Uno, S1
Aso, Y; Iijima, T; Jojima, T; Kato, K; Kishi, H; Maejima, Y; Sakurai, S; Shimizu, M; Shimomura, K; Usui, I1
Abe, T; Fujihara, K; Ishizawa, M; Kaku, K; Matsubayashi, Y; Nojima, T; Sone, H; Suganami, H; Tanaka, S; Yoshida, A1
Pinto Pereira, L; Rambaran, K; Teelucksingh, S1
de Zeeuw, D; Lambers Heerspink, HJ; Leslie, B; List, J; Wie, L1
Bello, NT; Verpeut, JL; Walters, AL1
Broedl, UC; Jones, R; Kovacs, CS; Rattunde, H; Seshiah, V; Swallow, R; Woerle, HJ1
Bolinder, J; Johansson, L; Langkilde, AM; Ljunggren, Ö; Parikh, S; Sjöström, CD; Sugg, J; Wilding, J1
Parikh, S; Rohwedder, K; Sugg, J; Wilding, JP; Woo, V1
Bilo, HJ; Drion, I; Goudswaard, AN; Holleman, F; Kleefstra, N; van Hateren, KJ1
Alba, M; Canovatchel, W; Cefalu, WT; Edwards, R; Jodar, E; Kim, KA; Meininger, G; Stenlöf, K; Tong, C1
Black, S; Canovatchel, W; Charpentier, G; González-Gálvez, G; Hollander, P; Law, G; Mathieu, C; Meininger, G; Usiskin, K; Vercruysse, F; Wilding, JP1
Hardy, E; Jabbour, SA; Parikh, S; Sugg, J1
le Roux, CW; Miras, AD1
Ledford, H1
Grandy, S; Hashemi, M; Langkilde, AM; Parikh, S; Sjöström, CD1
García, SD; Sanz, AD; Sanz, SD1
Albarrán, OG; Ampudia-Blasco, FJ1
Hayashizaki, Y; Kihara, R; Kurosaki, E; Li, Q; Mitsuoka, K; Miyoshi, S; Muramatsu, Y; Sasamata, M; Shibasaki, M; Tahara, A; Takasu, T; Tomiyama, H; Uchiyama, Y; Yokono, M1
Forst, T; Goldenberg, R; Guthrie, R; Meininger, G; Stein, P; Vijapurkar, U; Yee, J1
Athanasiadou, E; Bekiari, E; Karagiannis, T; Liakos, A; Mainou, M; Papatheodorou, K; Sarigianni, M; Tsapas, A1
Inoue, S; Kaku, K; Kiyosue, A; Langkilde, AM; Tokudome, T; Ueda, N; Yang, J1
Guthrie, R; Slee, A; Traina, S1
Broedl, UC; Frappin, G; Jelaska, A; Kim, G; Rosenstock, J; Salsali, A; Woerle, HJ1
Farrell, K; Heise, T; Natarajan, J; Plum-Mörschel, L; Polidori, D; Rothenberg, P; Sha, S; Sica, D; Wang, SS1
Broedl, UC; Haneda, M; Inagaki, N; Kadowaki, T; Koiwai, K; Rattunde, H; Taniguchi, A; Terauchi, Y; Woerle, HJ1
Adam, G; Berthiller, F; Hennig-Pauka, I; Moll, WD; Nagl, V; Schwartz-Zimmermann, HE; Woechtl, B1
Angelopoulos, TP; Doupis, J1
Inagaki, N; Kondo, K; Kuki, H; Susuta, Y; Takahashi, N; Yoshinari, T1
Arias, P; Balis, DA; Canovatchel, W; Langslet, G; Leiter, LA; Meininger, G; Millington, D; Vercruysse, F; Xie, J; Yoon, KH1
Dobbins, R; Dorey, DJ; Kler, L; Lorimer, JD; O'Connor-Semmes, R; Sykes, AP; Walker, S; Wilkison, WO1
Almond, SR; Dobbins, R; Kemp, GL; Kler, L; O'Connor-Semmes, R; Sykes, AP; Walker, S; Wilkison, WO1
Broedl, UC; Green, A; Narko, K; Salsali, A; Tikkanen, I; Woerle, HJ; Zeller, C1
Mediavilla Bravo, JJ1
Ishikawa, H; Kashiwagi, A; Kazuta, K; Takahashi, H; Ueyama, E; Utsuno, A; Yoshida, S1
Alba, M; Capuano, G; de Zeeuw, D; Desai, M; Fulcher, G; Jiang, J; Mahaffey, KW; Matthews, D; Meininger, G; Neal, B; Perkovic, V; Shaw, W; Vercruysse, F; Ways, K1
Broedl, UC; DeFronzo, RA; Kaste, R; Lewin, A; Liu, D; Patel, S; Woerle, HJ1
Davis, SN; Hedrington, MS1
Mikhail, N1
Cornell, S1
Blevins, T1
Bergenheim, K; Callan, L; Charokopou, M; Lister, S; McEwan, P; Postema, R; Roudaut, M; Tolley, K; Townsend, R1
Hashemi, M; Johnsson, E; Ptaszynska, A; Sjöström, CD; Sugg, J1
Pickl, S1
Broedl, UC; Jelaska, A; Kim, G; Rosenstock, J; Woerle, HJ; Zeller, C1
Banks, P; Bode, BW; Buse, JB; Cefalu, WT; Garg, SK; Heptulla, R; Lapuerta, P; Rendell, M; Rosenstock, J; Sands, AT; Strumph, P; Zambrowicz, BP1
Broedl, UC; Cescutti, J; Eilbracht, J; Famulla, S; Johansen, OE; Kaspers, S; Pieber, TR; Soleymanlou, N; Woerle, HJ1
Crowe, S; Ferrannini, E; Ferrannini, G; Hach, T; Hall, KD; Sanghvi, A1
Fath, R1
Abbas, A; Bustamante, M; Farah, Z; Gosavi, S; Mukherjee, D; Said, S; Shami, W; Syed, SH; Teleb, M1
Broedl, UC; Christiansen, AV; Kim, G; Merker, L; Roden, M; Roux, F; Salsali, A; Stella, P; Woerle, HJ1
Chilton, R; Johansen, OE; Tikkanen, I1
Demirci-Tansel, C; Gurel-Gurevin, E; Mericli, F; Ustunova, S; Yazici-Tutunis, S1
Broedl, UC; Chilton, R; Crowe, S; Johansen, OE; Lund, SS; McGuire, DK; Neeland, IJ; Woerle, HJ1
Shyangdan, DS; Uthman, OA; Waugh, N1
Isogawa, A; Ohki, T; Tagawa, K; Toda, N1
Furuke, S; Kanno, K; Komiya, C; Miyachi, Y; Ogawa, Y; Shiba, K; Shimazu, N; Tsuchiya, K; Yamaguchi, S1
Davies, MJ; Htike, ZZ; Khunti, K; Webb, DR; Youssef, D; Zaccardi, F1
Laubner, K; Seufert, J1
Amini, S; Eriksson, JW; Johnsson, E; Lundkvist, P; Pereira, MJ; Sjöström, CD1
Aronne, LJ; Mauer, EA; Rathi, S; Shukla, AP; Thomas, CE1
Cui, W; Li, D; Song, Y; Tang, H; Wang, T; Zhai, S; Zhang, J1
Close, KL; Dove, AE; Gao, HX; Marathe, PH; Odeh, SA1
González-Ortiz, M; Martínez-Abundis, E; Méndez-Del Villar, M; Ramírez-Rodríguez, AM1
Almodóvar-Ruiz, F; Feo-Ortega, G; Gorgojo-Martínez, JJ; Sanz-Velasco, A; Serrano-Moreno, C1
Kramer, MHH; Muskiet, MHA; Nieuwdorp, M; Tonneijck, L; van Bommel, EJM; van Raalte, DH1
Fiedorek, FT; List, JF; Morales, E; Tang, W; Woo, V1
Feng, Y; Kasichayanula, S; List, J; Pfister, M; Zhang, L1
Gao, J; Huang, Y; Huang, Z; Li, J; Li, P; Liu, Y; Shao, X; Wu, Q; Xu, D1
Cullen, MJ; Devenny, JJ; Godonis, HE; Harvey, SJ; Pelleymounter, MA; Rooney, S1
Pahor, A; Parikh, S; Rohwedder, K; Soler, NG; Sugg, J; Wilding, JP; Woo, V1
Aggarwal, N; Arbit, D; Canovatchel, W; Capuano, G; Polidori, D; Rosenstock, J; Usiskin, K; Zhao, Y1
Bailey, CJ; Iqbal, N; List, JF; T'joen, C1
Arguiri, E; Cengel, KA; Christofidou-Solomidou, M; Dukes, F; Grieshaber, PA; Pietrofesa, R; Solomides, CC; Turowski, J; Tyagi, S1
Alba, M; Canovatchel, W; Cefalu, WT; Kim, KA; Meininger, G; Stenlöf, K; Tong, C; Usiskin, K1
Ferrannini, E; Hantel, S; Pinnetti, S; Seewaldt-Becker, E; Seman, L; Woerle, HJ1
Allison, DB; Baker, BA; Coffey, CS; Steiner, D1
Boozer, CN; Herron, AJ1
Balan, K; Dunger, N; Falk, W; Hausmann, M; Herfarth, H; Menzel, K; Obermeier, F; Paper, DH; Rogler, G; Schoelmerich, J1

Reviews

22 review(s) available for glucose, (beta-d)-isomer and Weight Reduction

ArticleYear
Benefits of SGLT2 Inhibitors Beyond Glycemic Control - A Focus on Metabolic, Cardiovascular and Renal Outcomes.
    Current diabetes reviews, 2018, Volume: 14, Issue:6

    Topics: Benzhydryl Compounds; Blood Pressure; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glucosides; Glycated Hemoglobin; Humans; Kidney Diseases; Randomized Controlled Trials as Topic; Sodium-Glucose Transporter 2 Inhibitors; Weight Loss

2018
The role of SGLT2 inhibitors in managing type 2 diabetes.
    JAAPA : official journal of the American Academy of Physician Assistants, 2018, Volume: 31, Issue:6

    Topics: Benzhydryl Compounds; Bridged Bicyclo Compounds, Heterocyclic; Canagliflozin; Diabetes Mellitus, Type 2; Glucose; Glucosides; Glycated Hemoglobin; Glycosuria; Humans; Hypoglycemic Agents; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Weight Loss

2018
Use of SGLT2 inhibitors in type 2 diabetes: weighing the risks and benefits.
    Diabetologia, 2018, Volume: 61, Issue:10

    Topics: Benzhydryl Compounds; Blood Glucose; Blood Pressure; Body Weight; Bone and Bones; Canagliflozin; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Ketoacidosis; Glucosides; Humans; Hypoglycemic Agents; Ketosis; Kidney; Neoplasms; Randomized Controlled Trials as Topic; Risk Assessment; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Weight Loss

2018
The actions of SGLT2 inhibitors on metabolism, renal function and blood pressure.
    Diabetologia, 2018, Volume: 61, Issue:10

    Topics: Adiposity; Blood Glucose; Blood Pressure; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Glomerular Filtration Rate; Glucosides; Humans; Hyperglycemia; Hypoglycemic Agents; Kidney; Kidney Function Tests; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Weight Loss

2018
Empagliflozin reduces blood pressure and uric acid in patients with type 2 diabetes mellitus: a systematic review and meta-analysis.
    Journal of human hypertension, 2019, Volume: 33, Issue:4

    Topics: Adult; Aged; Benzhydryl Compounds; Biomarkers; Blood Glucose; Blood Pressure; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Female; Glucosides; Glycated Hemoglobin; Humans; Lipids; Male; Middle Aged; Randomized Controlled Trials as Topic; Risk Assessment; Risk Factors; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome; Uric Acid; Weight Loss

2019
[SGLT-2 inhibitors: diabetes treatment by glycosuria; literature review on the effect of dapagliflozin].
    Nederlands tijdschrift voor geneeskunde, 2013, Volume: 157, Issue:38

    Topics: Benzhydryl Compounds; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Metformin; Netherlands; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome; Weight Loss

2013
Can medical therapy mimic the clinical efficacy or physiological effects of bariatric surgery?
    International journal of obesity (2005), 2014, Volume: 38, Issue:3

    Topics: Anti-Obesity Agents; Bariatric Surgery; Benzazepines; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Exercise; Feeding Behavior; Female; Fructose; Glucagon-Like Peptide-1 Receptor; Glucosides; Glycated Hemoglobin; Homeostasis; Humans; Islet Amyloid Polypeptide; Lactones; Male; Minimally Invasive Surgical Procedures; Obesity, Morbid; Orlistat; Phentermine; Receptors, Glucagon; Topiramate; Treatment Outcome; Weight Loss

2014
[Type 2 diabetes mellitus and obesity: should we treat the obesity or the diabetes?].
    Medicina clinica, 2013, Volume: 141 Suppl 2

    Topics: Bariatric Surgery; Benzhydryl Compounds; Causality; Comorbidity; Diabetes Mellitus, Type 2; Diet, Diabetic; Diet, Reducing; Disease Management; Evidence-Based Medicine; Exercise Therapy; Glucagon-Like Peptide 1; Glucosides; Humans; Hyperinsulinism; Hypoglycemic Agents; Insulin Resistance; Metabolic Syndrome; Obesity; Practice Guidelines as Topic; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Weight Loss

2013
[Dapagliflozin, the first SGLT-2 inhibitor in the treatment of type 2 diabetes].
    Medicina clinica, 2013, Volume: 141 Suppl 2

    Topics: Benzhydryl Compounds; Biological Transport, Active; Blood Glucose; Clinical Trials, Phase III as Topic; Diabetes Mellitus, Type 2; Disease Susceptibility; Drug Evaluation, Preclinical; Drug Therapy, Combination; Glucose; Glucosides; Glycated Hemoglobin; Glycosuria; Half-Life; Humans; Hypoglycemic Agents; Kidney Tubules, Proximal; Molecular Structure; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome; Urinary Tract Infections; Weight Loss

2013
Efficacy and safety of empagliflozin for type 2 diabetes: a systematic review and meta-analysis.
    Diabetes, obesity & metabolism, 2014, Volume: 16, Issue:10

    Topics: Benzhydryl Compounds; Blood Glucose; Blood Pressure; Body Weight; Diabetes Mellitus, Type 2; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Odds Ratio; Randomized Controlled Trials as Topic; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome; Weight Loss

2014
Sodium-Glucose linked transporter 2 (SGLT2) inhibitors--fighting diabetes from a new perspective.
    Advances in therapy, 2014, Volume: 31, Issue:6

    Topics: Benzhydryl Compounds; Blood Pressure; Canagliflozin; Diabetes Mellitus, Type 2; Glucose; Glucosides; Humans; Hypoglycemic Agents; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome; Weight Loss

2014
Ipragliflozin , a sodium-glucose cotransporter 2 inhibitor, in the treatment of type 2 diabetes.
    Expert opinion on drug metabolism & toxicology, 2015, Volume: 11, Issue:4

    Topics: Diabetes Mellitus, Type 2; Drug Interactions; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes; Weight Loss

2015
Use of sodium-glucose cotransporter type 2 inhibitors in older adults with type 2 diabetes mellitus.
    Southern medical journal, 2015, Volume: 108, Issue:2

    Topics: Aged; Benzhydryl Compounds; Canagliflozin; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Evidence-Based Medicine; Glucosides; Humans; Hypoglycemic Agents; Meta-Analysis as Topic; Randomized Controlled Trials as Topic; Risk Factors; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes; Treatment Outcome; Weight Loss

2015
Review of empagliflozin monotherapy for previously untreated patients with type 2 diabetes mellitus: Comparison with sitagliptin.
    Postgraduate medicine, 2015, Volume: 127, Issue:3

    Topics: Adult; Benzhydryl Compounds; Blood Pressure; Diabetes Mellitus, Type 2; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Pyrazines; Sitagliptin Phosphate; Treatment Outcome; Triazoles; Weight Loss

2015
Dapagliflozin-induced weight loss affects 24-week glycated haemoglobin and blood pressure levels.
    Diabetes, obesity & metabolism, 2015, Volume: 17, Issue:8

    Topics: Benzhydryl Compounds; Blood Pressure; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Sodium-Glucose Transport Proteins; Treatment Outcome; Weight Loss

2015
A Review of Sodium Glucose Co-transporter 2 Inhibitors Canagliflozin, Dapagliflozin and Empagliflozin.
    Cardiovascular & hematological agents in medicinal chemistry, 2015, Volume: 13, Issue:2

    Topics: Benzhydryl Compounds; Canagliflozin; Diabetes Mellitus, Type 2; Drug Approval; Glucosides; Humans; Sodium-Glucose Transporter 2 Inhibitors; United States; Weight Loss

2015
Potential role of sodium glucose cotransporter 2 inhibitors in the treatment of hypertension.
    Current opinion in nephrology and hypertension, 2016, Volume: 25, Issue:2

    Topics: Benzhydryl Compounds; Blood Pressure; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diuretics; Glucosides; Humans; Hypertension; Hypoglycemic Agents; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Vascular Resistance; Weight Loss

2016
SGLT-2 receptor inhibitors for treating patients with type 2 diabetes mellitus: a systematic review and network meta-analysis.
    BMJ open, 2016, Feb-24, Volume: 6, Issue:2

    Topics: Bayes Theorem; Benzhydryl Compounds; Blood Pressure; Canagliflozin; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Metformin; Sodium-Glucose Transporter 2 Inhibitors; Sorbitol; Weight Loss

2016
Efficacy and safety of sodium-glucose co-transporter-2 inhibitors in type 2 diabetes mellitus: systematic review and network meta-analysis.
    Diabetes, obesity & metabolism, 2016, Volume: 18, Issue:8

    Topics: B-Cell Activating Factor; Benzhydryl Compounds; Blood Glucose; Body Weight; Canagliflozin; Cholesterol, HDL; Diabetes Mellitus, Type 2; Fasting; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Network Meta-Analysis; Odds Ratio; Reproductive Tract Infections; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome; Urinary Tract Infections; Weight Loss

2016
[Novel therapeutic options in patients with type 2 diabetes and high cardiovascular risk].
    Deutsche medizinische Wochenschrift (1946), 2016, Volume: 141, Issue:11

    Topics: Administration, Oral; Benzhydryl Compounds; Blood Glucose; Blood Pressure; Cardiovascular Diseases; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Glucosides; Heart Failure; Humans; Hypoglycemic Agents; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Survival Rate; Treatment Outcome; Weight Loss

2016
Sodium-glucose co-transporter 2 inhibitors in addition to insulin therapy for management of type 2 diabetes mellitus: A meta-analysis of randomized controlled trials.
    Diabetes, obesity & metabolism, 2017, Volume: 19, Issue:1

    Topics: Benzhydryl Compounds; Blood Glucose; Body Weight; Canagliflozin; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin; Odds Ratio; Randomized Controlled Trials as Topic; Reproductive Tract Infections; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome; Urinary Tract Infections; Weight Loss

2017
SGLT2 Inhibition in the Diabetic Kidney-From Mechanisms to Clinical Outcome.
    Clinical journal of the American Society of Nephrology : CJASN, 2017, Apr-03, Volume: 12, Issue:4

    Topics: Albuminuria; Benzhydryl Compounds; Blood Glucose; Blood Pressure; Canagliflozin; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Glucose; Glucosides; Humans; Hypoglycemic Agents; Lipid Metabolism; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Weight Loss

2017

Trials

56 trial(s) available for glucose, (beta-d)-isomer and Weight Reduction

ArticleYear
Effects of Dapagliflozin and Combination Therapy With Exenatide on Food-Cue Induced Brain Activation in Patients With Type 2 Diabetes.
    The Journal of clinical endocrinology and metabolism, 2022, 05-17, Volume: 107, Issue:6

    Topics: Benzhydryl Compounds; Blood Glucose; Brain; Cues; Diabetes Mellitus, Type 2; Double-Blind Method; Exenatide; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Middle Aged; Obesity; Sodium-Glucose Transporter 2 Inhibitors; Weight Loss

2022
The effects of empagliflozin, dietary energy restriction, or both on appetite-regulatory gut peptides in individuals with type 2 diabetes and overweight or obesity: The SEESAW randomized, double-blind, placebo-controlled trial.
    Diabetes, obesity & metabolism, 2022, Volume: 24, Issue:8

    Topics: Adult; Aged; Appetite; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Double-Blind Method; Ghrelin; Glucagon-Like Peptide 1; Glucose; Glucosides; Humans; Hypoglycemic Agents; Middle Aged; Obesity; Overweight; Peptide YY; Sodium-Glucose Transporter 2 Inhibitors; Weight Loss

2022
Combination therapy with exenatide decreases the dapagliflozin-induced changes in brain responses to anticipation and consumption of palatable food in patients with type 2 diabetes: A randomized controlled trial.
    Diabetes, obesity & metabolism, 2022, Volume: 24, Issue:8

    Topics: Benzhydryl Compounds; Blood Glucose; Brain; Diabetes Mellitus, Type 2; Double-Blind Method; Exenatide; Glucose; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Obesity; Sodium; Sodium-Glucose Transporter 2 Inhibitors; Weight Loss

2022
Brain Activation in Response to Low-Calorie Food Pictures: An Explorative Analysis of a Randomized Trial With Dapagliflozin and Exenatide.
    Frontiers in endocrinology, 2022, Volume: 13

    Topics: Benzhydryl Compounds; Brain; Diabetes Mellitus, Type 2; Exenatide; Glucosides; Humans; Hypoglycemic Agents; Sodium-Glucose Transporter 2 Inhibitors; Weight Loss

2022
Impact of dapagliflozin treatment on renal function and diuretics use in acute heart failure: a pilot study.
    Open heart, 2022, Volume: 9, Issue:1

    Topics: Benzhydryl Compounds; Diuretics; Female; Glucosides; Heart Failure; Humans; Kidney; Male; Pilot Projects; Sodium Potassium Chloride Symporter Inhibitors; Stroke Volume; Ventricular Function, Left; Weight Loss

2022
Efficacy of dapagliflozin versus sitagliptin on cardiometabolic risk factors in Japanese patients with type 2 diabetes: a prospective, randomized study (DIVERSITY-CVR).
    Cardiovascular diabetology, 2020, 01-07, Volume: 19, Issue:1

    Topics: Aged; Benzhydryl Compounds; Biomarkers; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Female; Glucosides; Glycated Hemoglobin; Humans; Japan; Male; Metabolic Syndrome; Middle Aged; Prospective Studies; Risk Assessment; Risk Factors; Sitagliptin Phosphate; Sodium-Glucose Transporter 2 Inhibitors; Time Factors; Treatment Outcome; Weight Loss

2020
Efficacy of the treatment with dapagliflozin and metformin compared to metformin monotherapy for weight loss in patients with class III obesity: a randomized controlled trial.
    Trials, 2020, Feb-14, Volume: 21, Issue:1

    Topics: Adult; Benzhydryl Compounds; Clinical Trials, Phase IV as Topic; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Glucosides; Humans; Male; Metformin; Mexico; Middle Aged; Obesity, Morbid; Prediabetic State; Randomized Controlled Trials as Topic; Severity of Illness Index; Treatment Outcome; Waist Circumference; Weight Loss; Young Adult

2020
Effects of Empagliflozin Treatment on Glycerol-Derived Hepatic Gluconeogenesis in Adults with Obesity: A Randomized Clinical Trial.
    Obesity (Silver Spring, Md.), 2020, Volume: 28, Issue:7

    Topics: Adipose Tissue; Adult; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Gluconeogenesis; Glucosides; Glycerol; Humans; Intra-Abdominal Fat; Liver; Male; Middle Aged; Obesity; Placebos; Weight Loss

2020
Favorable effect of sodium-glucose cotransporter 2 inhibitor, dapagliflozin, on non-alcoholic fatty liver disease compared with pioglitazone.
    Journal of diabetes investigation, 2021, Volume: 12, Issue:7

    Topics: Aged; Benzhydryl Compounds; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Female; gamma-Glutamyltransferase; Glucosides; Glycated Hemoglobin; Humans; Linear Models; Male; Middle Aged; Non-alcoholic Fatty Liver Disease; Pioglitazone; Prospective Studies; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome; Triglycerides; Waist Circumference; Weight Loss

2021
Efficacy and safety of dapagliflozin in acute heart failure: Rationale and design of the DICTATE-AHF trial.
    American heart journal, 2021, Volume: 232

    Topics: Acute Disease; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Diabetic Ketoacidosis; Disease Progression; Glucosides; Heart Failure; Hospital Mortality; Humans; Hyperglycemia; Hypoglycemia; Hypoglycemic Agents; Hypotension; Hypovolemia; Insulin; Natriuresis; Natriuretic Peptide, Brain; Patient Readmission; Peptide Fragments; Randomized Controlled Trials as Topic; Renal Insufficiency, Chronic; Sodium Potassium Chloride Symporter Inhibitors; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome; Weight Loss

2021
Exenatide, Dapagliflozin, or Phentermine/Topiramate Differentially Affect Metabolic Profiles in Polycystic Ovary Syndrome.
    The Journal of clinical endocrinology and metabolism, 2021, 09-27, Volume: 106, Issue:10

    Topics: Adolescent; Adult; Benzhydryl Compounds; Blood Glucose; Drug Therapy, Combination; Exenatide; Female; Glucose Tolerance Test; Glucosides; Humans; Hypoglycemic Agents; Metformin; Middle Aged; Obesity; Phentermine; Polycystic Ovary Syndrome; Prospective Studies; Single-Blind Method; Topiramate; Treatment Outcome; Weight Loss; Young Adult

2021
Dapagliflozin once daily plus exenatide once weekly in obese adults without diabetes: Sustained reductions in body weight, glycaemia and blood pressure over 1 year.
    Diabetes, obesity & metabolism, 2017, Volume: 19, Issue:9

    Topics: Adiposity; Anti-Obesity Agents; Benzhydryl Compounds; Body Mass Index; Cardiovascular Diseases; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Exenatide; Female; Follow-Up Studies; Ghrelin; Glucosides; Humans; Hypoglycemic Agents; Male; Membrane Transport Modulators; Middle Aged; Obesity; Peptides; Prediabetic State; Proof of Concept Study; Risk Factors; Sodium-Glucose Transport Proteins; Sweden; Venoms; Weight Loss

2017
Tofogliflozin decreases body fat mass and improves peripheral insulin resistance.
    Diabetes, obesity & metabolism, 2018, Volume: 20, Issue:5

    Topics: Adiposity; Anti-Obesity Agents; Benzhydryl Compounds; Biomarkers; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Electric Impedance; Glucose Clamp Technique; Glucosides; Glycated Hemoglobin; Hyperglycemia; Hypoglycemia; Insulin Resistance; Overweight; Sodium-Glucose Transporter 2 Inhibitors; Weight Loss

2018
Empagliflozin as adjunct to insulin in Japanese participants with type 1 diabetes: Results of a 4-week, double-blind, randomized, placebo-controlled phase 2 trial.
    Diabetes, obesity & metabolism, 2018, Volume: 20, Issue:9

    Topics: Adult; Aged; Benzhydryl Compounds; Diabetes Mellitus, Type 1; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Glucosides; Glycosuria; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin; Japan; Male; Middle Aged; Treatment Outcome; Weight Loss; Young Adult

2018
Efficacy and Safety of Dapagliflozin in Patients With Inadequately Controlled Type 1 Diabetes: The DEPICT-1 52-Week Study.
    Diabetes care, 2018, Volume: 41, Issue:12

    Topics: Adult; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 1; Double-Blind Method; Drug Therapy, Combination; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Male; Placebos; Treatment Outcome; Weight Loss

2018
Impact of dapagliflozin, an SGLT2 inhibitor, on serum levels of soluble dipeptidyl peptidase-4 in patients with type 2 diabetes and non-alcoholic fatty liver disease.
    International journal of clinical practice, 2019, Volume: 73, Issue:5

    Topics: Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Female; gamma-Glutamyltransferase; Glucosides; Hepatitis; Humans; Inflammation; Insulin Resistance; Intra-Abdominal Fat; Male; Middle Aged; Non-alcoholic Fatty Liver Disease; Sodium-Glucose Transporter 2 Inhibitors; Subcutaneous Fat; Weight Loss

2019
Attenuation of Weight Loss Through Improved Antilipolytic Effect in Adipose Tissue Via the SGLT2 Inhibitor Tofogliflozin.
    The Journal of clinical endocrinology and metabolism, 2019, 09-01, Volume: 104, Issue:9

    Topics: Adipose Tissue; Benzhydryl Compounds; Biomarkers; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Fatty Acids, Nonesterified; Female; Follow-Up Studies; Glucosides; Glycated Hemoglobin; Humans; Insulin Resistance; Lipolysis; Male; Middle Aged; Prognosis; Prospective Studies; Sodium-Glucose Transporter 2 Inhibitors; Weight Loss

2019
Sodium-glucose cotransporter 2 inhibition as a potential treatment for idiopathic oedema.
    Medical hypotheses, 2019, Volume: 130

    Topics: Anxiety; Autonomic Nervous System; Benzhydryl Compounds; Blood Pressure; Cross-Over Studies; Edema; Electrolytes; Female; Glucose Intolerance; Glucosides; Hemodynamics; Humans; Models, Theoretical; Randomized Controlled Trials as Topic; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome; Weight Loss

2019
Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes.
    Diabetes, obesity & metabolism, 2013, Volume: 15, Issue:9

    Topics: Adolescent; Adult; Aged; Benzhydryl Compounds; Blood Glucose; Blood Pressure; Diabetes Mellitus, Type 2; Diuretics; Double-Blind Method; Drug Therapy, Combination; Female; Glucosides; Humans; Hydrochlorothiazide; Hypoglycemic Agents; Male; Middle Aged; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome; Weight Loss

2013
Empagliflozin improves glycaemic and weight control as add-on therapy to pioglitazone or pioglitazone plus metformin in patients with type 2 diabetes: a 24-week, randomized, placebo-controlled trial.
    Diabetes, obesity & metabolism, 2014, Volume: 16, Issue:2

    Topics: Aged; Benzhydryl Compounds; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glucosides; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Pioglitazone; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiazolidinediones; Treatment Outcome; Weight Loss

2014
Dapagliflozin maintains glycaemic control while reducing weight and body fat mass over 2 years in patients with type 2 diabetes mellitus inadequately controlled on metformin.
    Diabetes, obesity & metabolism, 2014, Volume: 16, Issue:2

    Topics: Absorptiometry, Photon; Benzhydryl Compounds; Blood Glucose; Body Mass Index; Bone Density; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glucosides; Glycated Hemoglobin; Humans; Male; Metformin; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome; Weight Loss

2014
Dapagliflozin in patients with type 2 diabetes receiving high doses of insulin: efficacy and safety over 2 years.
    Diabetes, obesity & metabolism, 2014, Volume: 16, Issue:2

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Genital Diseases, Female; Genital Diseases, Male; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin; Male; Metformin; Middle Aged; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome; Urinary Tract Infections; Weight Loss

2014
Long-term efficacy and safety of canagliflozin monotherapy in patients with type 2 diabetes inadequately controlled with diet and exercise: findings from the 52-week CANTATA-M study.
    Current medical research and opinion, 2014, Volume: 30, Issue:2

    Topics: Blood Glucose; Blood Pressure; Body Weight; Canagliflozin; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Diet; Double-Blind Method; Exercise; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Middle Aged; Placebos; Pyrazines; Sitagliptin Phosphate; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes; Treatment Outcome; Triazoles; Triglycerides; Weight Loss

2014
Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sulphonylurea: a randomised trial.
    International journal of clinical practice, 2013, Volume: 67, Issue:12

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Blood Glucose; Blood Pressure; Canagliflozin; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin-Secreting Cells; Lipid Metabolism; Male; Metformin; Middle Aged; Sulfonylurea Compounds; Thiophenes; Treatment Outcome; Weight Loss; Young Adult

2013
Dapagliflozin is effective as add-on therapy to sitagliptin with or without metformin: a 24-week, multicenter, randomized, double-blind, placebo-controlled study.
    Diabetes care, 2014, Volume: 37, Issue:3

    Topics: Benzhydryl Compounds; Blood Glucose; Blood Pressure; Body Weight; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Pyrazines; Sitagliptin Phosphate; Treatment Outcome; Triazoles; Urinary Tract Infections; Weight Loss

2014
Changes in weight loss-related quality of life among type 2 diabetes mellitus patients treated with dapagliflozin.
    Diabetes, obesity & metabolism, 2014, Volume: 16, Issue:7

    Topics: Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glucosides; Health Status; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Quality of Life; Risk Assessment; Surveys and Questionnaires; Treatment Outcome; Weight Loss

2014
Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes on background metformin and pioglitazone.
    Diabetes, obesity & metabolism, 2014, Volume: 16, Issue:5

    Topics: Blood Glucose; Blood Pressure; Canagliflozin; Candidiasis; Diabetes Mellitus, Type 2; Diuretics, Osmotic; Double-Blind Method; Drug Therapy, Combination; Female; Genital Diseases, Female; Genital Diseases, Male; Glucosides; Humans; Hypoglycemic Agents; Lipids; Male; Metformin; Middle Aged; Pioglitazone; Pyrazines; Sitagliptin Phosphate; Thiazolidinediones; Thiophenes; Treatment Outcome; Triazoles; Weight Loss

2014
Efficacy and safety of dapagliflozin monotherapy in Japanese patients with type 2 diabetes inadequately controlled by diet and exercise.
    Diabetes, obesity & metabolism, 2014, Volume: 16, Issue:11

    Topics: Asian People; Benzhydryl Compounds; Biomarkers; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Double-Blind Method; Fasting; Female; Follow-Up Studies; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Middle Aged; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome; Weight Loss

2014
The impact of weight loss on weight-related quality of life and health satisfaction: results from a trial comparing canagliflozin with sitagliptin in triple therapy among people with type 2 diabetes.
    Postgraduate medicine, 2014, Volume: 126, Issue:3

    Topics: Adult; Age Factors; Aged; Body Weight; Canagliflozin; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glucosides; Glycated Hemoglobin; Health Behavior; Humans; Hypoglycemic Agents; Male; Middle Aged; Personal Satisfaction; Pyrazines; Quality of Life; Self Efficacy; Sex Factors; Sexual Behavior; Sitagliptin Phosphate; Thiophenes; Triazoles; Weight Loss

2014
Improved glucose control with weight loss, lower insulin doses, and no increased hypoglycemia with empagliflozin added to titrated multiple daily injections of insulin in obese inadequately controlled type 2 diabetes.
    Diabetes care, 2014, Volume: 37, Issue:7

    Topics: Aged; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin; Male; Metformin; Middle Aged; Obesity; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome; Weight Loss

2014
Effect of the sodium glucose co-transporter 2 inhibitor canagliflozin on plasma volume in patients with type 2 diabetes mellitus.
    Diabetes, obesity & metabolism, 2014, Volume: 16, Issue:11

    Topics: Adult; Aged; Antihypertensive Agents; Blood Glucose; Blood Pressure; Body Weight; Canagliflozin; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Dose-Response Relationship, Drug; Drug Therapy, Combination; Fasting; Female; Glucosides; Glycated Hemoglobin; Humans; Hypertension; Hypoglycemic Agents; Kidney; Male; Metformin; Middle Aged; Plasma Volume; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes; Treatment Outcome; Water-Electrolyte Balance; Weight Loss

2014
Empagliflozin monotherapy in Japanese patients with type 2 diabetes mellitus: a randomized, 12-week, double-blind, placebo-controlled, phase II trial.
    Advances in therapy, 2014, Volume: 31, Issue:6

    Topics: Aged; Benzhydryl Compounds; Blood Glucose; Blood Pressure; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Drug Monitoring; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Japan; Male; Middle Aged; Treatment Outcome; Weight Loss

2014
Efficacy and safety of canagliflozin monotherapy in Japanese patients with type 2 diabetes inadequately controlled with diet and exercise: a 24-week, randomized, double-blind, placebo-controlled, Phase III study.
    Expert opinion on pharmacotherapy, 2014, Volume: 15, Issue:11

    Topics: Aged; Blood Glucose; Blood Pressure; Canagliflozin; Diabetes Mellitus, Type 2; Double-Blind Method; Exercise Therapy; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Japan; Ketone Bodies; Lipids; Male; Middle Aged; Thiophenes; Treatment Outcome; Weight Loss

2014
Canagliflozin provides durable glycemic improvements and body weight reduction over 104 weeks versus glimepiride in patients with type 2 diabetes on metformin: a randomized, double-blind, phase 3 study.
    Diabetes care, 2015, Volume: 38, Issue:3

    Topics: Blood Glucose; Body Weight; Canagliflozin; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glucosides; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Metformin; Middle Aged; Sulfonylurea Compounds; Thiophenes; Time Factors; Treatment Outcome; Weight Loss

2015
Randomized trial showing efficacy and safety of twice-daily remogliflozin etabonate for the treatment of type 2 diabetes.
    Diabetes, obesity & metabolism, 2015, Volume: 17, Issue:1

    Topics: Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Follow-Up Studies; Glucosides; Glycated Hemoglobin; Humans; Hyperglycemia; Hypertriglyceridemia; Hypoglycemia; Hypoglycemic Agents; Intention to Treat Analysis; Membrane Transport Modulators; Middle Aged; Patient Dropouts; Pioglitazone; Prodrugs; Pyrazoles; Sodium-Glucose Transporter 2 Inhibitors; Thiazolidinediones; Weight Loss

2015
Randomized efficacy and safety trial of once-daily remogliflozin etabonate for the treatment of type 2 diabetes.
    Diabetes, obesity & metabolism, 2015, Volume: 17, Issue:1

    Topics: Cohort Studies; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Follow-Up Studies; Glucosides; Glycated Hemoglobin; Humans; Hyperglycemia; Hypoglycemic Agents; Intention to Treat Analysis; Membrane Transport Modulators; Middle Aged; Patient Dropouts; Pioglitazone; Prodrugs; Pyrazoles; Sodium-Glucose Transporter 2 Inhibitors; Thiazolidinediones; Weight Loss

2015
Empagliflozin reduces blood pressure in patients with type 2 diabetes and hypertension.
    Diabetes care, 2015, Volume: 38, Issue:3

    Topics: Analysis of Variance; Antihypertensive Agents; Benzhydryl Compounds; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Double-Blind Method; Drug Administration Schedule; Female; Glucosides; Glycated Hemoglobin; Humans; Hypertension; Hypoglycemic Agents; Male; Middle Aged; Treatment Outcome; Weight Loss

2015
A randomized, double-blind, placebo-controlled study on long-term efficacy and safety of ipragliflozin treatment in patients with type 2 diabetes mellitus and renal impairment: results of the long-term ASP1941 safety evaluation in patients with type 2 dia
    Diabetes, obesity & metabolism, 2015, Volume: 17, Issue:2

    Topics: Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Renal Insufficiency; Thiophenes; Time Factors; Treatment Outcome; Weight Loss

2015
Efficacy and safety of canagliflozin, an inhibitor of sodium-glucose cotransporter 2, when used in conjunction with insulin therapy in patients with type 2 diabetes.
    Diabetes care, 2015, Volume: 38, Issue:3

    Topics: Blood Glucose; Blood Pressure; Canagliflozin; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Glomerular Filtration Rate; Glucosides; Glycated Hemoglobin; Glycosuria; Humans; Hypoglycemia; Hypoglycemic Agents; Hypovolemia; Insulin; Male; Middle Aged; Mycoses; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes; Treatment Outcome; Urinary Tract Infections; Weight Loss

2015
Combination of empagliflozin and linagliptin as second-line therapy in subjects with type 2 diabetes inadequately controlled on metformin.
    Diabetes care, 2015, Volume: 38, Issue:3

    Topics: Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Linagliptin; Male; Metformin; Middle Aged; Purines; Quinazolines; Treatment Outcome; Weight Loss

2015
The cost-effectiveness of dapagliflozin versus sulfonylurea as an add-on to metformin in the treatment of Type 2 diabetes mellitus.
    Diabetic medicine : a journal of the British Diabetic Association, 2015, Volume: 32, Issue:7

    Topics: Benzhydryl Compounds; Cohort Studies; Cost-Benefit Analysis; Diabetes Complications; Diabetes Mellitus, Type 2; Drug Resistance; Drug Therapy, Combination; Female; Glucosides; Health Care Costs; Humans; Hyperglycemia; Hypoglycemia; Hypoglycemic Agents; Male; Metformin; Middle Aged; Overweight; Quality-Adjusted Life Years; Risk; Sodium-Glucose Transport Proteins; Sulfonylurea Compounds; United Kingdom; Weight Loss

2015
Impact of empagliflozin added on to basal insulin in type 2 diabetes inadequately controlled on basal insulin: a 78-week randomized, double-blind, placebo-controlled trial.
    Diabetes, obesity & metabolism, 2015, Volume: 17, Issue:10

    Topics: Aged; Benzhydryl Compounds; Blood Glucose; Blood Pressure; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin Detemir; Male; Middle Aged; Treatment Outcome; Urinary Tract Infections; Weight Loss

2015
Sotagliflozin, a Dual SGLT1 and SGLT2 Inhibitor, as Adjunct Therapy to Insulin in Type 1 Diabetes.
    Diabetes care, 2015, Volume: 38, Issue:7

    Topics: Adult; Benzhydryl Compounds; Blood Glucose; Combined Modality Therapy; Diabetes Mellitus, Type 1; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Glucosides; Glycosides; Humans; Hypoglycemic Agents; Insulin; Male; Middle Aged; Treatment Outcome; Weight Loss; Young Adult

2015
Empagliflozin as adjunct to insulin in patients with type 1 diabetes: a 4-week, randomized, placebo-controlled trial (EASE-1).
    Diabetes, obesity & metabolism, 2015, Volume: 17, Issue:10

    Topics: Adult; Austria; Benzhydryl Compounds; Diabetes Mellitus, Type 1; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Germany; Glucosides; Glycated Hemoglobin; Glycosuria; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin; Male; Middle Aged; Treatment Outcome; Weight Loss

2015
Safety, tolerability and effects on cardiometabolic risk factors of empagliflozin monotherapy in drug-naïve patients with type 2 diabetes: a double-blind extension of a Phase III randomized controlled trial.
    Cardiovascular diabetology, 2015, Dec-23, Volume: 14

    Topics: Adult; Aged; Benzhydryl Compounds; Biomarkers; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Middle Aged; Sitagliptin Phosphate; Time Factors; Treatment Outcome; Weight Loss

2015
Empagliflozin reduces body weight and indices of adipose distribution in patients with type 2 diabetes mellitus.
    Diabetes & vascular disease research, 2016, Volume: 13, Issue:2

    Topics: Adiposity; Adult; Aged; Benzhydryl Compounds; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Female; Glucosides; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Obesity; Weight Loss

2016
Dapagliflozin once-daily and exenatide once-weekly dual therapy: A 24-week randomized, placebo-controlled, phase II study examining effects on body weight and prediabetes in obese adults without diabetes.
    Diabetes, obesity & metabolism, 2017, Volume: 19, Issue:1

    Topics: Adipose Tissue; Adult; Aged; Benzhydryl Compounds; Blood Glucose; Blood Pressure; Body Composition; Body Weight; Double-Blind Method; Drug Therapy, Combination; Exenatide; Female; Glucose Intolerance; Glucosides; Humans; Hypoglycemic Agents; Injections, Subcutaneous; Magnetic Resonance Imaging; Male; Middle Aged; Nausea; Obesity; Peptides; Prediabetic State; Treatment Outcome; Venoms; Weight Loss

2017
Effect of dapagliflozin administration on metabolic syndrome, insulin sensitivity, and insulin secretion.
    Minerva endocrinologica, 2018, Volume: 43, Issue:3

    Topics: Adult; Benzhydryl Compounds; Blood Glucose; Double-Blind Method; Female; Glucosides; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Insulin Secretion; Lipids; Male; Metabolic Syndrome; Middle Aged; Weight Loss

2018
Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes.
    Diabetes care, 2009, Volume: 32, Issue:4

    Topics: Adolescent; Adult; Aged; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Diuretics; Dose-Response Relationship, Drug; Female; Glucosides; Glycated Hemoglobin; Glycosuria; Humans; Hyperglycemia; Hypoglycemic Agents; Male; Metformin; Middle Aged; Placebos; Sodium-Glucose Transport Proteins; Weight Loss; Young Adult

2009
Dapagliflozin treatment in patients with different stages of type 2 diabetes mellitus: effects on glycaemic control and body weight.
    Diabetes, obesity & metabolism, 2010, Volume: 12, Issue:6

    Topics: Benzhydryl Compounds; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Middle Aged; Sodium-Glucose Transporter 2; Weight Loss

2010
Long-term efficacy of dapagliflozin in patients with type 2 diabetes mellitus receiving high doses of insulin: a randomized trial.
    Annals of internal medicine, 2012, Mar-20, Volume: 156, Issue:6

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Benzhydryl Compounds; Blood Glucose; Blood Pressure; Child; Diabetes Mellitus, Type 2; Female; Genital Diseases, Female; Genital Diseases, Male; Glucosides; Glycated Hemoglobin; Heart Rate; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin; Male; Middle Aged; Sodium-Glucose Transport Proteins; Treatment Outcome; Weight Loss; Young Adult

2012
Dose-ranging effects of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to metformin in subjects with type 2 diabetes.
    Diabetes care, 2012, Volume: 35, Issue:6

    Topics: Adolescent; Adult; Aged; Blood Glucose; Canagliflozin; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Glucosides; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Metformin; Middle Aged; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes; Treatment Outcome; Weight Loss; Young Adult

2012
Dapagliflozin monotherapy in drug-naïve patients with diabetes: a randomized-controlled trial of low-dose range.
    Diabetes, obesity & metabolism, 2012, Volume: 14, Issue:10

    Topics: Benzhydryl Compounds; Blood Glucose; Canada; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Follow-Up Studies; Glucosides; Glycated Hemoglobin; Humans; India; Male; Mexico; Middle Aged; Puerto Rico; Russia; South Africa; Treatment Outcome; United States; Weight Loss

2012
Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise.
    Diabetes, obesity & metabolism, 2013, Volume: 15, Issue:4

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Blood Glucose; Canagliflozin; Cholesterol, HDL; Diabetes Mellitus, Type 2; Diet; Double-Blind Method; Exercise; Fasting; Female; Glucosides; Humans; Hypoglycemic Agents; Male; Middle Aged; Postprandial Period; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes; Treatment Outcome; Triglycerides; Weight Loss

2013
A Phase IIb, randomized, placebo-controlled study of the SGLT2 inhibitor empagliflozin in patients with type 2 diabetes.
    Diabetes, obesity & metabolism, 2013, Volume: 15, Issue:8

    Topics: Adult; Aged; Aged, 80 and over; Argentina; Benzhydryl Compounds; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Europe; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Nasopharyngitis; Republic of Korea; Russia; Sodium-Glucose Transporter 2 Inhibitors; Taiwan; Thirst; Treatment Outcome; Ukraine; Urination Disorders; Weight Loss

2013
A randomized double-blind placebo-controlled clinical trial of a product containing ephedrine, caffeine, and other ingredients from herbal sources for treatment of overweight and obesity in the absence of lifestyle treatment.
    International journal of obesity and related metabolic disorders : journal of the International Association for the Study of Obesity, 2004, Volume: 28, Issue:11

    Topics: Adult; Anti-Obesity Agents; Benzyl Alcohols; Body Mass Index; Caffeine; Cola; Double-Blind Method; Drug Combinations; Ephedra sinica; Ephedrine; Female; Glucosides; Humans; Logistic Models; Male; Middle Aged; Obesity; Phytotherapy; Plants, Medicinal; Salix; Statistics, Nonparametric; Time Factors; Weight Loss

2004

Other Studies

40 other study(ies) available for glucose, (beta-d)-isomer and Weight Reduction

ArticleYear
Green tea polyphenol extract attenuates zymosan-induced non-septic shock in mice.
    Shock (Augusta, Ga.), 2006, Volume: 26, Issue:4

    Topics: Animals; Camellia sinensis; Flavonoids; Male; Mice; Phenols; Phytotherapy; Plant Extracts; Polyphenols; Shock; Weight Loss; Zymosan

2006
Stem cell factor-deficient mice have a dysregulation of cytokine production during local inflammation.
    European cytokine network, 1998, Volume: 9, Issue:1

    Topics: Animals; Ascitic Fluid; Body Weight; Cytokines; Disease Models, Animal; Female; Hypoglycemia; Inflammation; Irritants; Mice; Mice, Mutant Strains; Peritoneal Cavity; Peritonitis; Stem Cell Factor; Turpentine; Weight Loss; Zymosan

1998
Antihypertensive and metabolic effects of empagliflozin in Ren-2 transgenic rats, an experimental non-diabetic model of hypertension.
    Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2021, Volume: 144

    Topics: Adiposity; Animals; Anti-Inflammatory Agents; Antihypertensive Agents; Antioxidants; Benzhydryl Compounds; Blood Pressure; Disease Models, Animal; Energy Metabolism; Glucosides; Hypertension; Male; Rats, Sprague-Dawley; Rats, Transgenic; Renin; Weight Loss

2021
Quantifying the relationship between dapagliflozin and loss of weight in type 1 diabetes mellitus patients.
    Journal of clinical pharmacy and therapeutics, 2022, Volume: 47, Issue:2

    Topics: Age Factors; Benzhydryl Compounds; Body Weight; Diabetes Mellitus, Type 1; Dose-Response Relationship, Drug; Glucosides; Humans; Hypoglycemic Agents; Randomized Controlled Trials as Topic; Retrospective Studies; Weight Loss

2022
Predictors for successful weight reduction during treatment with Dapagliflozin among patients with type 2 diabetes mellitus in primary care.
    BMC primary care, 2022, 05-27, Volume: 23, Issue:1

    Topics: Benzhydryl Compounds; Body Weight; Diabetes Mellitus, Type 2; Female; Glucosides; Humans; Male; Metformin; Primary Health Care; Weight Loss

2022
Evaluation of the Cost Per Patient Achieving Treatment Targets with Oral Semaglutide: A Short-Term Cost-Effectiveness Analysis in the United States.
    Advances in therapy, 2019, Volume: 36, Issue:12

    Topics: Benzhydryl Compounds; Blood Glucose; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Glucagon-Like Peptides; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Liraglutide; Middle Aged; Sitagliptin Phosphate; United States; Weight Loss

2019
Safety and effectiveness of tofogliflozin in Japanese patients with type 2 diabetes mellitus: Results of 24-month interim analysis of a long-term post-marketing study (J-STEP/LT).
    Journal of diabetes investigation, 2020, Volume: 11, Issue:4

    Topics: Aged; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Female; Glucosides; Glycated Hemoglobin; Humans; Japan; Male; Middle Aged; Product Surveillance, Postmarketing; Prospective Studies; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome; Weight Loss

2020
Valproate intoxication in a patient with bipolar I disorder due to SGLT2 inhibitor-induced weight reduction.
    Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences, 2020, Volume: 28, Issue:1

    Topics: Aged; Antimanic Agents; Benzhydryl Compounds; Bipolar Disorder; Diabetes Mellitus, Type 2; Drug Interactions; Glucosides; Humans; Male; Sodium-Glucose Transporter 2 Inhibitors; Tremor; Valproic Acid; Weight Loss

2020
Inhibitory effect of a weight-loss Chinese herbal formula RCM-107 on pancreatic α-amylase activity: Enzymatic and in silico approaches.
    PloS one, 2020, Volume: 15, Issue:4

    Topics: Animals; Anti-Obesity Agents; Carbohydrate Metabolism; Catechin; Cholestenones; Drugs, Chinese Herbal; Enzyme Assays; Flavanones; Glucosides; Humans; Molecular Docking Simulation; Obesity; Pancreatic alpha-Amylases; Swine; Weight Loss

2020
Dietary Cyanidin-3-Glucoside Attenuates High-Fat-Diet-Induced Body-Weight Gain and Impairment of Glucose Tolerance in Mice via Effects on the Hepatic Hormone FGF21.
    The Journal of nutrition, 2020, 08-01, Volume: 150, Issue:8

    Topics: Animals; Anthocyanins; Diet, High-Fat; Dietary Fats; Fibroblast Growth Factors; Gene Expression Regulation; Glucagon-Like Peptide 1; Glucose Intolerance; Glucosides; Incretins; Leptin; Liver; Male; Mice; Random Allocation; Weight Gain; Weight Loss

2020
Association of estimated plasma volume and weight loss after long-term administration and subsequent discontinuation of the sodium-glucose cotransporter-2 inhibitor tofogliflozin.
    Diabetes, obesity & metabolism, 2021, Volume: 23, Issue:7

    Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucose; Glucosides; Humans; Pharmaceutical Preparations; Plasma Volume; Sodium; Sodium-Glucose Transporter 2 Inhibitors; Weight Loss

2021
The Sodium Glucose Cotransporter 2 Inhibitor Ipragliflozin Promotes Preferential Loss of Fat Mass in Non-obese Diabetic Goto-Kakizaki Rats.
    Biological & pharmaceutical bulletin, 2017, Volume: 40, Issue:5

    Topics: Absorptiometry, Photon; Adipose Tissue; Animals; Body Composition; Diabetes Mellitus, Type 2; Diet, High-Fat; Eating; Glucosides; Glycosuria; Hypoglycemic Agents; Male; Rats; Rats, Wistar; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes; Weight Loss

2017
Dapagliflozin therapy for type 2 diabetes in primary care: Changes in HbA1c, weight and blood pressure over 2 years follow-up.
    Primary care diabetes, 2017, Volume: 11, Issue:5

    Topics: Aged; Benzhydryl Compounds; Biomarkers; Blood Glucose; Blood Pressure; Databases, Factual; Diabetes Mellitus, Type 2; Drug Prescriptions; Female; Follow-Up Studies; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Logistic Models; Male; Middle Aged; Multivariate Analysis; Odds Ratio; Practice Patterns, Physicians'; Primary Health Care; Time Factors; Treatment Outcome; United Kingdom; Weight Loss

2017
Pooled analysis of Phase III trials indicate contrasting influences of renal function on blood pressure, body weight, and HbA1c reductions with empagliflozin.
    Kidney international, 2018, Volume: 93, Issue:1

    Topics: Adult; Aged; Benzhydryl Compounds; Biomarkers; Blood Pressure; Clinical Trials, Phase III as Topic; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Down-Regulation; Female; Glomerular Filtration Rate; Glucosides; Glycated Hemoglobin; Humans; Kidney; Male; Middle Aged; Randomized Controlled Trials as Topic; Renal Insufficiency, Chronic; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome; Weight Loss

2018
Effect of sodium-glucose cotransporter 2 (SGLT2) inhibition on weight loss is partly mediated by liver-brain-adipose neurocircuitry.
    Biochemical and biophysical research communications, 2017, 11-04, Volume: 493, Issue:1

    Topics: Adipose Tissue; Animals; Anti-Obesity Agents; Benzhydryl Compounds; Brain; Glucosides; Liver; Male; Mice; Mice, Inbred C57BL; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Vagotomy; Vagus Nerve; Weight Loss

2017
Efficacy of sodium glucose cotransporter 2 inhibitors as an adjunct treatment for patients with diabetes type 2.
    Medicina clinica, 2019, 06-07, Volume: 152, Issue:11

    Topics: Adult; Aged; Benzhydryl Compounds; Blood Glucose; Blood Pressure; Body Weight; Canagliflozin; Cholesterol, HDL; Diabetes Mellitus, Type 2; Female; Glucosides; Glycated Hemoglobin; Humans; Insulin; Male; Middle Aged; Retrospective Studies; Sodium-Glucose Transporter 2 Inhibitors; Weight Loss

2019
Effects of ipragliflozin on glycemic control, appetite and its related hormones: A prospective, multicenter, open-label study (SOAR-KOBE Study).
    Journal of diabetes investigation, 2019, Volume: 10, Issue:5

    Topics: Appetite; Biomarkers; Blood Glucose; Body Mass Index; Body Weight; Diabetes Mellitus, Type 2; Eating; Female; Follow-Up Studies; Ghrelin; Glucosides; Glycated Hemoglobin; Glycemic Index; Humans; Leptin; Male; Middle Aged; Prognosis; Prospective Studies; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes; Weight Loss

2019
Impact of body mass index on the efficacy and safety of ipragliflozin in Japanese patients with type 2 diabetes mellitus: A subgroup analysis of 3-month interim results from the Specified Drug Use Results Survey of Ipragliflozin Treatment in Type 2 Diabet
    Journal of diabetes investigation, 2019, Volume: 10, Issue:5

    Topics: Biomarkers; Blood Glucose; Body Mass Index; Body Weight; Diabetes Mellitus, Type 2; Female; Follow-Up Studies; Glucosides; Glycated Hemoglobin; Humans; Japan; Male; Middle Aged; Product Surveillance, Postmarketing; Prognosis; Safety; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes; Weight Loss

2019
Citrus aurantium and Rhodiola rosea in combination reduce visceral white adipose tissue and increase hypothalamic norepinephrine in a rat model of diet-induced obesity.
    Nutrition research (New York, N.Y.), 2013, Volume: 33, Issue:6

    Topics: Adipose Tissue, White; Animals; Citrus; Diet, High-Fat; Disaccharides; Dopamine; Glucosides; Hypothalamus; Kaolin; Male; Monoamine Oxidase; Norepinephrine; Obesity; Phenols; Phytotherapy; Plant Extracts; Plant Roots; Prefrontal Cortex; Rats; Rats, Sprague-Dawley; Rhodiola; Synephrine; Weight Loss

2013
Dapagliflozin (Forxiga) for type 2 diabetes?
    Drug and therapeutics bulletin, 2013, Volume: 51, Issue:9

    Topics: Adult; Animals; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Drug Approval; Glucosides; Humans; Hypoglycemic Agents; United Kingdom; Weight Loss

2013
Diabetes drugs ride a bumpy road.
    Nature, 2013, Dec-12, Volume: 504, Issue:7479

    Topics: Benzhydryl Compounds; Blood Glucose; Clinical Trials as Topic; Diabetes Mellitus; Glucosides; Heart Diseases; Humans; Hypoglycemic Agents; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Weight Loss

2013
SGLT2 selective inhibitor ipragliflozin reduces body fat mass by increasing fatty acid oxidation in high-fat diet-induced obese rats.
    European journal of pharmacology, 2014, Mar-15, Volume: 727

    Topics: Adiposity; Animals; Anti-Obesity Agents; Biomarkers; Blood Glucose; Diet, High-Fat; Disease Models, Animal; Energy Metabolism; Fatty Acids; Glucosides; Glycosuria; Hypoglycemic Agents; Lipid Metabolism; Obesity; Oxidation-Reduction; Rats; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes; Time Factors; Up-Regulation; Weight Loss

2014
Metabolism of the masked mycotoxin deoxynivalenol-3-glucoside in pigs.
    Toxicology letters, 2014, Aug-17, Volume: 229, Issue:1

    Topics: Administration, Oral; Animals; Anorexia; Biological Availability; Biotransformation; Chromatography, High Pressure Liquid; Feces; Glucosides; Indicators and Reagents; Injections, Intravenous; Intestinal Absorption; Male; Mass Spectrometry; Mycotoxins; Reproducibility of Results; Swine; Trichothecenes; Vomiting; Weight Loss

2014
[Contributions of SGLT-2 and new drugs under investigation].
    Semergen, 2014, Volume: 40 Suppl 2

    Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Drug Design; Drug Therapy, Combination; Glucose; Glucosides; Humans; Hypoglycemic Agents; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Weight Loss

2014
Combination therapy for patients with uncontrolled type 2 diabetes mellitus: adding empagliflozin to pioglitazone or pioglitazone plus metformin.
    Expert opinion on drug safety, 2015, Volume: 14, Issue:5

    Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Female; Glucosides; Humans; Hypoglycemic Agents; Male; Metformin; Sodium-Glucose Transporter 2 Inhibitors; Thiazolidinediones; Weight Loss

2015
[Weight also counts for patients].
    MMW Fortschritte der Medizin, 2015, Apr-02, Volume: 157, Issue:6

    Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucosides; Humans; Obesity; Randomized Controlled Trials as Topic; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Weight Loss

2015
Energy Balance After Sodium-Glucose Cotransporter 2 Inhibition.
    Diabetes care, 2015, Volume: 38, Issue:9

    Topics: Adult; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Energy Metabolism; Female; Glucosides; Humans; Hypoglycemic Agents; Male; Middle Aged; Sodium-Glucose Transporter 2; Weight Loss

2015
[Positive experience with SGLT-2 inhibitor in general practice].
    MMW Fortschritte der Medizin, 2015, Jul-23, Volume: 157, Issue:13

    Topics: Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glucosides; Humans; Hypoglycemic Agents; Meta-Analysis as Topic; Randomized Controlled Trials as Topic; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Weight Loss

2015
Possible effects of Phillyrea latifolia on weight loss in rats fed a high-energy diet.
    Pharmaceutical biology, 2016, Volume: 54, Issue:10

    Topics: Animals; Anti-Obesity Agents; Biomarkers; Blood Glucose; Chlorogenic Acid; Diet, High-Fat; Disease Models, Animal; Energy Intake; Glucosides; Hypoglycemic Agents; Intestine, Small; Lipids; Liver; Luteolin; Male; Obesity; Oleaceae; Phytotherapy; Plant Extracts; Plant Leaves; Plants, Medicinal; Rats, Wistar; Time Factors; Weight Loss

2016
Effectiveness of Ipragliflozin, a Sodium-Glucose Co-transporter 2 Inhibitor, as a Second-line Treatment for Non-Alcoholic Fatty Liver Disease Patients with Type 2 Diabetes Mellitus Who Do Not Respond to Incretin-Based Therapies Including Glucagon-like Pep
    Clinical drug investigation, 2016, Volume: 36, Issue:4

    Topics: Alanine Transaminase; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Female; Glucagon-Like Peptide 1; Glucosides; Humans; Incretins; Liver Cirrhosis; Male; Middle Aged; Non-alcoholic Fatty Liver Disease; Retrospective Studies; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes; Weight Loss

2016
Ipragliflozin Improves Hepatic Steatosis in Obese Mice and Liver Dysfunction in Type 2 Diabetic Patients Irrespective of Body Weight Reduction.
    PloS one, 2016, Volume: 11, Issue:3

    Topics: Adipose Tissue; Adult; Animals; Body Weight; Diabetes Mellitus, Type 2; Diet, High-Fat; Drug Evaluation, Preclinical; Energy Intake; Epididymis; Glucose; Glucosides; Humans; Hyperphagia; Hypoglycemic Agents; Insulin Resistance; Leptin; Lipids; Liver; Male; Mice; Mice, Inbred C57BL; Mice, Obese; Non-alcoholic Fatty Liver Disease; Obesity; Organ Size; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes; Weight Loss

2016
Low adoption of weight loss medications: A comparison of prescribing patterns of antiobesity pharmacotherapies and SGLT2s.
    Obesity (Silver Spring, Md.), 2016, Volume: 24, Issue:9

    Topics: Anti-Obesity Agents; Benzhydryl Compounds; Databases, Factual; Drug Prescriptions; Glucosides; Humans; Hypoglycemic Agents; Obesity; Phentermine; Practice Patterns, Physicians'; Retrospective Studies; United States; Weight Loss

2016
Obesity Week 2016 Annual Meeting.
    Journal of diabetes, 2017, Volume: 9, Issue:3

    Topics: Benzhydryl Compounds; Cardiovascular Diseases; Congresses as Topic; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypoglycemic Agents; Liraglutide; Prediabetic State; Quality of Life; Treatment Outcome; Weight Loss

2017
Real-world effectiveness and safety of dapagliflozin therapy added to a GLP1 receptor agonist in patients with type 2 diabetes.
    Nutrition, metabolism, and cardiovascular diseases : NMCD, 2017, Volume: 27, Issue:2

    Topics: Aged; Benzhydryl Compounds; Biomarkers; Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glucagon-Like Peptide-1 Receptor; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Incretins; Male; Middle Aged; Retrospective Studies; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Spain; Time Factors; Treatment Outcome; Weight Loss

2017
Antifibrosis effects of total glucosides of Danggui-Buxue-Tang in a rat model of bleomycin-induced pulmonary fibrosis.
    Journal of ethnopharmacology, 2011, Jun-14, Volume: 136, Issue:1

    Topics: Animals; Bleomycin; Collagen Type I; Disease Models, Animal; Dose-Response Relationship, Drug; Drugs, Chinese Herbal; Glucosides; Lung; Male; Phytotherapy; Pulmonary Fibrosis; Random Allocation; Rats; Rats, Wistar; Transforming Growth Factor beta1; Tumor Necrosis Factor-alpha; Weight Loss

2011
Weight loss induced by chronic dapagliflozin treatment is attenuated by compensatory hyperphagia in diet-induced obese (DIO) rats.
    Obesity (Silver Spring, Md.), 2012, Volume: 20, Issue:8

    Topics: 3-Hydroxybutyric Acid; Animals; Anti-Obesity Agents; Benzhydryl Compounds; Blood Glucose; Caloric Restriction; Diet; Dose-Response Relationship, Drug; Drinking; Energy Intake; Glucosides; Hyperphagia; Insulin; Male; Obesity; Oxygen Consumption; Rats; Rats, Sprague-Dawley; Respiration; Sodium-Glucose Transport Proteins; Treatment Outcome; Weight Loss

2012
Summaries for patients: Dapagliflozin treatment in patients with inadequately controlled type 2 diabetes despite the use of insulin.
    Annals of internal medicine, 2012, Mar-20, Volume: 156, Issue:6

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Benzhydryl Compounds; Blood Glucose; Child; Diabetes Mellitus, Type 2; Female; Genital Diseases, Female; Genital Diseases, Male; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin; Male; Middle Aged; Sodium-Glucose Transport Proteins; Treatment Outcome; Weight Loss; Young Adult

2012
Radioprotective role in lung of the flaxseed lignan complex enriched in the phenolic secoisolariciresinol diglucoside (SDG).
    Radiation research, 2012, Volume: 178, Issue:6

    Topics: Animals; Antioxidants; Butylene Glycols; Dietary Carbohydrates; Eating; Female; Flax; Glucosides; Inflammation; Lignans; Lung; Mice; Mice, Inbred C57BL; Phenols; Radiation Pneumonitis; Radiation-Protective Agents; Survival Analysis; Thorax; Weight Loss

2012
Simmondsin for weight loss in rats.
    International journal of obesity (2005), 2006, Volume: 30, Issue:7

    Topics: Acetonitriles; Animals; Appetite Depressants; Body Composition; Body Weight; Cyclohexanes; Dose-Response Relationship, Drug; Eating; Erythrocytes; Glucosides; Kidney; Leukocytes; Liver; Male; Obesity; Organ Size; Rats; Rats, Sprague-Dawley; Thinness; Weight Loss

2006
In vivo treatment with the herbal phenylethanoid acteoside ameliorates intestinal inflammation in dextran sulphate sodium-induced colitis.
    Clinical and experimental immunology, 2007, Volume: 148, Issue:2

    Topics: Acute Disease; Animals; Antioxidants; Chronic Disease; Colitis; Colon; Cytokines; Dextran Sulfate; Enzyme-Linked Immunosorbent Assay; Female; Glucosides; Inflammation Mediators; Intestinal Mucosa; Lymph Nodes; Macrophages; Mice; Mice, Inbred BALB C; Peroxidase; Phenols; Respiratory Burst; Weight Loss

2007